Open Label Study for the Functional Characterization of Drug Metabolism and Transport

Inclusion criteria

• Written informed consent obtained prior to study entry including informed consent for genetic research
• Both genders (male and female)
• Healthy adults aged ≥18 to <65 years
• Bodyweight not less than 48 kg and not more than 120 kg. BMI not less than 18 kg/m² and not greater than 33 kg/m².
• Smokers and nonsmokers. Smoking siblings will only be included if both siblings are smoking to a similar extend (+/- 10 cigarettes per day)
• healthy volunteers
• Dizygotic twins will only be included if both siblings are of the same gender, either male or female and triplets, quadruplets or other multiplets if at least two siblings of the same gender are considered.

Exclusion criteria

• Participation in a clinical trial involving the administration of medicines during the last 30 days or use of any other investigational or non-registered drug or vaccine during the study period or within 30 days preceding the first dose of study drugs
• Blood, plasma or thrombocyte donation during the last 30 days prior to application of the test drugs.
• Pregnancy or lactation period
• Any relevant clinical and pathological findings at physical examination, ECG, taking blood pressure or in clinical chemistry tests (deviation of more than 10% of the normal range).
• Positive signal from urinary drug test
• Raynaud's syndrome
• Taking any medication within 7 days before or during the trial with the following exceptions: Single doses of mild analgesics (e.g. aspirin, paracetamol, ibuprofen) an oral contraceptives.
• History of severe hypersensitivity reactions and anaphylaxis.
• History of intolerance or allergic reactions to or contraindication for any of the investigational products.
• Clinically significant diseases as judged by the investigator.
• Contraindication against MRI.